🧬 Mark Kotter - bit.bio - Part 3 | Success in Academia vs. Industry | Vital Things All Founders Should Know | The Importance of Company Culture | bit.bio & the Operating System of Life

Part 3 of 4. My guest for this week’s episode is Mark Kotter, neurosurgeon, stem cell biologist, and CEO and founder of bit.bio. Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery, and cell therapy. Bit.bio applies a patented safe harbor gene targeting approach to inducibly express transcription factor combinations that reprogram human-induced pluripotent stem cells into highly defined and mature human cell types. Bit.bio spun out of the University of Cambridge in 2016 and has since raised approximately $200 million from Arch Ventures, Foresight Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Pulau Capital, among others.